Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat.com Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech SectorBy Jeffrey Neal Johnson. Originally Published: 2/24/2026. 
Key Points - Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of roughly $245 per share, creating a divergence that has caught Wall Street's attention. This rally runs counter to the image of the healthcare giant as a slow-moving, boring stock. Over the last 30 days, shares have climbed about 14%, significantly outperforming the broader market during a period of uncertainty. That price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, reliable cash flow, and execution. For investors watching the ticker on Feb. 24, 2026, note a specific calendar event: today is the ex-dividend date for Johnson & Johnson. The stock price will likely drop by approximately the amount of the upcoming dividend payment—$1.30 per share—a mechanical market adjustment rather than a reflection of business performance. For income-focused investors, this technical dip often represents an attractive entry point rather than a sell signal. 64 Years of Unbroken Growth The primary argument for holding Johnson & Johnson during turbulent market cycles is its financial stability and role as a portfolio stabilizer. The company belongs to an elite group of equities known as Dividend Kings, firms that have increased their dividend payout for at least 50 consecutive years. Johnson & Johnson has raised its dividend for 64 consecutive years, a track record that spans multiple recessions, market crashes, and geopolitical conflicts. That reliability is a rare commodity in a market often dominated by speculative growth. Currently, the stock yields roughly 2.12%, based on an annual payout of $5.20 per share. While higher yields can be found in the bond market or in riskier sectors, the appeal here is the combination of growth and safety. Management projects free cash flow to reach about $21 billion in 2026, providing a substantial cushion to support dividends, invest in R&D, and manage legal expenses without heavy borrowing. For risk-averse investors, one compelling metric is the stock's Beta. Beta measures how much a stock moves compared to the overall market (S&P 500). A Beta of 1.0 means the stock moves in lockstep with the market. Johnson & Johnson currently has a Beta of just 0.35, meaning the stock has historically been about 65% less volatile than the broader market. When tech stocks swing, J&J tends to hold its ground. Adding JNJ to a portfolio heavy in technology acts as a mathematical shock absorber, dampening overall volatility while still providing equity exposure. Beyond the Patent Cliff: The Road to $100 Billion A common misconception about safe stocks is that they cannot grow. Johnson & Johnson is disproving that notion with a strategic pivot that appears to be paying off. Management has issued strong guidance for 2026, projecting full-year revenue to surpass the $100 billion threshold for the first time in the company's history. Alongside this revenue milestone, the company anticipates adjusted earnings per share (EPS) of about $11.53. This growth is driven by a reinvention of its pharmaceutical division, now branded as Innovative Medicine. Investors had worried about the patent cliff after Stelara, a blockbuster immunology drug, lost exclusivity in 2025. Typically, when a top drug faces generic competition, revenue collapses. J&J has mitigated that decline through the rapid rise of new blockbuster therapies. Two key assets are driving this resilience: - Darzalex: This oncology powerhouse is generating about $14 billion in annual sales and has cemented the company's leadership in treating multiple myeloma.
- Tremfya: Positioned as a successor to Stelara in some indications, Tremfya recently released strong three-year remission data for ulcerative colitis. Those clinical results help the company retain market share in the competitive immunology space even as older drugs fade.
The Tech in MedTech: High-Margin Technologies The growth story extends beyond pharmaceuticals into the MedTech division, which has refocused on high-growth, high-margin technologies. A notable example is the integration of Shockwave Medical, acquired to modernize the cardiovascular portfolio. Shockwave's intravascular lithotripsy (IVL) technology uses sonic pressure waves to safely break up calcified plaque in arteries, similar to how kidney stones are treated—an upgrade over traditional angioplasty balloons. By owning this technology, Johnson & Johnson has secured a high-growth asset that complements its existing cardiovascular and surgical businesses. The company is also advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals an intent to compete directly in the expanding soft-tissue robotics market. These high-tech devices carry higher profit margins and build sticky relationships with hospital systems, providing a long-term earnings tailwind that goes beyond basic consumables. Addition by Subtraction: The Orthopedics Strategy To sustain its growth trajectory and improve margins, management is reshaping the corporate structure. A major development is the potential separation or sale of the DePuy Synthes orthopedics business. Originally planned as a spin-off, recent reports indicate the company is exploring a significant divestiture. Divesting the orthopedics unit is an example of an addition-by-subtraction strategy. Orthopedics is a mature, lower-growth business compared with expanding fields like oncology and advanced cardiovascular devices. Shedding that slower unit would likely improve overall revenue growth and profit margins. A sale could also generate a substantial cash infusion—potentially billions—that could be used for acquisitions or share buybacks. Legal risk remains a critical factor. The company continues to face litigation over talc products, with a recent $1.5 billion verdict keeping the issue in the headlines. A new commercial lawsuit from Bayer over marketing claims for prostate cancer drugs has added noise to the news cycle. Still, the recent rally suggests the market is looking past those headlines. Bulls argue Johnson & Johnson has the financial depth to manage these liabilities without disrupting operations. With more than $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale, and roughly $21 billion in annual free cash flow, the company is well positioned to absorb settlements. That financial strength keeps legal battles a balance-sheet consideration rather than an existential threat to the dividend or core business. Capital Preservation With Upside Johnson & Johnson has evolved from a slow-moving conglomerate into a more focused, high-tech healthcare company. After shedding its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting its orthopedics unit, the company is concentrating on high-growth opportunities in pharmaceuticals and medical technology. While the stock is no longer a bargain, trading near all-time highs, it offers a blend of capital preservation and growth that is hard to find elsewhere. The combination of a 64-year dividend growth streak, a notably low volatility profile, and a clear path to $100 billion in revenue makes J&J a compelling option for 2026. For investors tired of the unpredictability in technology, Johnson & Johnson demonstrates that, in the current market environment, boring can be both beautiful and profitable.
| 
